open access

Vol 14, No 1 (2019)
Heart failure
Published online: 2019-04-10
Get Citation

Sacubitril/valsartan in clinical practice

Małgorzata Lelonek, Paweł Rubiś, Jakub Gierczyński, Agnieszka Pawlak
DOI: 10.5603/FC.2019.0002
·
Folia Cardiologica 2019;14(1):95-105.

open access

Vol 14, No 1 (2019)
Heart failure
Published online: 2019-04-10

Abstract

In a landmark multi-center, phase III, randomized controlled trial — PARADIGM-HF, that investigated long-term effects and safety of novel class of agents — angiotensin receptor antagonist/neprilisin inhibitor (ARNI) — LCZ696 (sacubitril/ /valsartan) in comparison with enalapril, clear clinical benefit was shown in patients with heart failure with reduced ejection fraction (HFrEF) who were subjected to sacubitril/valsartan. Sacubitril/valsartan (EntrestoTM) has been avai- lable in Poland for the last two years. The present document is a practical guide for all those physicians who would like to initiate this new therapy for the first time and also for those have gathered so far some experience with EntrestoTM. 

Abstract

In a landmark multi-center, phase III, randomized controlled trial — PARADIGM-HF, that investigated long-term effects and safety of novel class of agents — angiotensin receptor antagonist/neprilisin inhibitor (ARNI) — LCZ696 (sacubitril/ /valsartan) in comparison with enalapril, clear clinical benefit was shown in patients with heart failure with reduced ejection fraction (HFrEF) who were subjected to sacubitril/valsartan. Sacubitril/valsartan (EntrestoTM) has been avai- lable in Poland for the last two years. The present document is a practical guide for all those physicians who would like to initiate this new therapy for the first time and also for those have gathered so far some experience with EntrestoTM. 

Get Citation

Keywords

heart failure with reduced ejection fraction; sacubitril/valsartan

About this article
Title

Sacubitril/valsartan in clinical practice

Journal

Folia Cardiologica

Issue

Vol 14, No 1 (2019)

Pages

95-105

Published online

2019-04-10

DOI

10.5603/FC.2019.0002

Bibliographic record

Folia Cardiologica 2019;14(1):95-105.

Keywords

heart failure with reduced ejection fraction
sacubitril/valsartan

Authors

Małgorzata Lelonek
Paweł Rubiś
Jakub Gierczyński
Agnieszka Pawlak

References (20)
  1. Ponikowski P, Voors AA, Anker SD, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129–2200.
  2. McMurray JJV, Packer M, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371(11): 993–1004.
  3. McMurray JJV, Packer M, Desai AS, et al. PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013; 15(9): 1062–1073.
  4. Entresto™ Charakterystyka Produktu Leczniczego, 2015. https://www.novartis.pl/system/files/product-info/entresto_chpl_2018_06.pdf (31.01.2019).
  5. Lewis EF, Claggett BL, McMurray JJV, et al. Health-related quality of life outcomes in PARADIGM-HF. Circ Heart Fail. 2017; 10(8).
  6. Chandra A, Lewis EF, Claggett BL, et al. Effects of sacubitril/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiol. 2018; 3(6): 498–505.
  7. Nadruz W, Claggett BL, McMurray JJ, et al. PARADIGM-HF Investigators and Committees, PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015; 131(1): 54–61.
  8. Wytyczne oceny technologii medycznych (HTA, ang. health technology assessment). Wersja 3.0. Agencja Oceny Technologii Medycznych i Taryfikacji. Warszawa, sierpień 2016. http://www.aotm.gov.pl/www/wp-content/uploads/wytyczne_hta/2016/20160913_Wytyczne_AOTMiT.pdf (31.01.2019).
  9. Feature story. Real-world evidence: perceptions of cardiologists . https://www.acc.org/latest-in-cardiology/articles/2018/02/13/14/42/feature-story-real-world-evidence-perceptions-of-cardiologists (31.01.2019).
  10. Du X, Khamitova A, Kyhlstedt M, et al. Utilisation of real-world data from heart failure registries in OECD countries — a systematic review. IJC Heart & Vasculature. 2018; 19: 90–97.
  11. Aimo A, Seghieri C, Nuti S, et al. Building medical knowledge from real world registries: the case of heart failure. IJC Heart & Vasculature. 2018; 19: 98–99.
  12. Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF Registry. J Am Coll Cardiol. 2018; 72(4): 351–366.
  13. Wachter R et al. Dosing Patterns and Evolution of Clinical Parameters in Patients Prescribed Sacubitril /Valsartan in Germany. Poster presentation at: American Heart Association Scientific Sessions 2017. Nov 11-15, Anaheim, CA. . https://www.ahajournals.org/doi/abs/10.1161/circ.136.suppl_1.15751 (31.01.2019).
  14. Wachter R, Viriato D, Klebs S, et al. Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany. Postgrad Med. 2018; 130(3): 308–316.
  15. Canu A, et al. Results of a single center experience on 200 consecutive patients treated with Entresto (sacubitril/valsartan). Eur J Heart Fail. 2017; 19: 413–414.
  16. Bastien N, Haddad H, Bergeron S, et al. The PARASAIL study — patient reported outcomes from the Canadian real-world experience use of sacubitril/valsartan in patients with heart failure and reduced ejection fraction. Canadian J Cardiol. 2017; 33(10): S162–S163.
  17. Martens P, Beliën H, Dupont M, et al. Insights into implementation of sacubitril/valsartan into clinical practice. ESC Heart Fail. 2018; 5(3): 275–283.
  18. Murray G, et al. The use of sacubitril/valsartan: a real world experience in a high volume specialist heart failure service. Heart. 2017; 103: A8–A9.
  19. Kałużna-Oleksy M, Kolasa J, Migaj J, et al. Pierwsze doświadczenia kliniczne z przedstawicielem nowej grupy leków ARNI (sakubitril/walsartan) u pacjentów z niewydolnością serca z obniżoną frakcją wyrzutową lewej komory w Polsce. Kardiol Pol. 2018; 76(2): 381–387.
  20. Antol DD, Casebeer AW, DeClue RW, et al. An early view of real-world patient response to sacubitril/valsartan: a retrospective study of patients with heart failure with reduced ejection fraction. Adv Ther. 2018; 35(6): 785–795.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl